Molecular Probe for Cancer Detection Developed by Case Western Reserve University

Strategic Insights -

Researchers at Case Western Reserve University have developed a molecular probe for detecting cancer cells expressing a specific immunoglobulin superfamily cell adhesion molecule. The probe targets and binds to a proteolytically cleaved extracellular fragment of this molecule, allowing for the location and distribution of cancer cells to be determined in a tissue sample or in vivo. This innovation has the potential to improve surgical resection and patient survival rates for glioblastoma multiforme (GBM) and other types of cancer.

Key Takeaways:

  • The molecular probe is designed to detect cancer cells expressing an immunoglobulin superfamily cell adhesion molecule, specifically a proteolytically cleaved extracellular fragment.
  • The probe consists of a targeting agent that binds to the cleaved fragment and a detectable moiety that generates a signal upon imaging.
  • The detectable moiety can be detected using various imaging techniques, such as gamma imaging, positron emission tomography (PET) imaging, or computer tomography (CT) imaging.
  • The probe has the potential to improve surgical resection and patient survival rates for glioblastoma multiforme (GBM) and other types of cancer.
  • The probe targets a specific tyrosine phosphatase (PTP) type IIb protein, which is expressed by cancer cells.
  • The probe can be used to detect cancer cells in a tissue sample or in vivo.

Statistics:

  • Glioblastoma multiforme (GBM) has a median survival of about one year from diagnosis.
  • Nearly all glioblastomas recur locally, making early detection crucial for improving survival rates.
  • The molecular probe has the potential to improve surgical resection and patient survival rates for GBM and other types of cancer.
  • The probe targets a specific tyrosine phosphatase (PTP) type IIb protein.
  • The detectable moiety can be detected using various imaging techniques.
  • The probe consists of a targeting agent and a detectable moiety that generates a signal upon imaging.

Sources:

  • Brady-Kalnay, Susann. Methods and compositions for the detection of cancer. U.S. Patent Number 12377172, filed March 26, 2019, and published online on August 5, 2025.
  • Ichimura K, Ohgaki H, Kleihues P, Collins V P (2004) Molecular pathogenesis of astrocytic tumours. J Neurooncol 70:137-160.
  • Louis D N, Ohgaki H, Wiestler O D, Cavenee W K (2007) World Health Organization Classification of Tumours of the Nervous System, 4th Edition. Lyon: IARC.
  • Louis D N (2006) Molecular pathology of malignant gliomas. Annu Rev Pathol 1:97-117.
  • Furnari F B, Fenton T, Bachoo R M, Mukasa A, Stommel J M, Stegh A, Hahn W C, Ligon K L, Louis D N, Brennan C, Chin L, DePinho R A, Cavenee W K (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21:2683-2710.